A Prospective Randomized Controlled Pilot Study to Assess the Response and Tolerability of Cold Atmospheric Plasma for Rosacea

Overview

Journal Skin Pharmacol Physiol

Publisher Karger

Specialties Dermatology
Pharmacology
Physiology

Date 2023 Jul 25

PMID 37490882

Authors

Stella Hofmeyer

Frank Weber

Sandra Gerds

Steffen Emmert

Alexander Thiem

Affiliations

Soon will be listed here.

Abstract

Introduction: Rosacea is a common, facial, chronic inflammatory skin disease. Due to its complex pathogenesis, adequate therapy of rosacea can be challenging. An innovative recent therapeutic tool is cold atmospheric plasma (CAP), which is already established in the treatment of chronic wounds and promising in different other skin diseases.

Methods: In a split-face pilot study we investigated dielectric-barrier-discharged CAP in erythemato-telangiectatic (ETR) and/or papulopustular rosacea (PPR). CAP treatment was applied on lesional skin of a randomized side once daily (90 s/area) for 6 weeks. The other untreated side served as control. Co-primary endpoints were ≥1 improvement of the Investigator Global Assessment (IGA) score on the treated side compared to control and a decline of the Dermatology Life Quality Index (DLQI) after 6 weeks. Secondary endpoints included inflammatory lesion count (papules and pustules), skin redness intensity and erythema size. Adverse events (AEs) were recorded constantly. Additionally, participants were weekly assessed for symptoms, skin condition, trigger factors, skin care, treatment success, and local tolerance parameters. All p values were calculated using the Wilcoxon signed-rank test.

Results: Twelve subjects (ETR, n = 3; ETR and PPR, n = 9) completed the study. DLQI was significantly improved after 6 weeks (p = 0.007). On the CAP-treated side, lesions (p = 0.007) and erythema size (p = 0.041) were significantly reduced compared to the control. IGA (p = 0.2) and skin redness intensity (p = 0.5) did not differ significantly between control and CAP-treated side. No serious AEs occurred and treatment was well tolerated.

Conclusion: CAP is a promising new treatment of rosacea, especially for PPR.

Citing Articles

Use of Non-Thermal Plasma as Postoperative Therapy in Anal Fistula: Clinical Experience and Results.

Lopez-Callejas R, Velasco-Garcia P, Betancourt-Angeles M, Rodriguez-Mendez B, Berrones-Stringel G, Jaramillo-Martinez C Biomedicines. 2024; 12(8).

PMID: 39200330 PMC: 11351551. DOI: 10.3390/biomedicines12081866.

Cold Atmospheric Pressure Plasma-Activated Medium Modulates Cellular Functions of Human Mesenchymal Stem/Stromal Cells In Vitro.

Hahn O, Waheed T, Sridharan K, Huemerlehner T, Staehlke S, Thurling M Int J Mol Sci. 2024; 25(9).

PMID: 38732164 PMC: 11084445. DOI: 10.3390/ijms25094944.

References

Augustin M, Herberger K, Hintzen S, Heigel H, Franzke N, Schafer I . Prevalence of skin lesions and need for treatment in a cohort of 90 880 workers. Br J Dermatol. 2011; 165(4):865-73. DOI: 10.1111/j.1365-2133.2011.10436.x. View

Chen G, Chen Z, Wen D, Wang Z, Li H, Zeng Y . Transdermal cold atmospheric plasma-mediated immune checkpoint blockade therapy. Proc Natl Acad Sci U S A. 2020; 117(7):3687-3692. PMC: 7035610. DOI: 10.1073/pnas.1917891117. View

van Welzen A, Hoch M, Wahl P, Weber F, Rode S, Tietze J . The Response and Tolerability of a Novel Cold Atmospheric Plasma Wound Dressing for the Healing of Split Skin Graft Donor Sites: A Controlled Pilot Study. Skin Pharmacol Physiol. 2021; 34(6):328-336. PMC: 8619757. DOI: 10.1159/000517524. View

Wen X, Xin Y, Hamblin M, Jiang X . Applications of cold atmospheric plasma for transdermal drug delivery: a review. Drug Deliv Transl Res. 2020; 11(3):741-747. DOI: 10.1007/s13346-020-00808-2. View

Holmes A, Steinhoff M . Integrative concepts of rosacea pathophysiology, clinical presentation and new therapeutics. Exp Dermatol. 2016; 26(8):659-667. DOI: 10.1111/exd.13143. View

Miebach L, Freund E, Clemen R, Kersting S, Partecke L, Bekeschus S . Gas plasma-oxidized sodium chloride acts via hydrogen peroxide in a model of peritoneal carcinomatosis. Proc Natl Acad Sci U S A. 2022; 119(31):e2200708119. PMC: 9351543. DOI: 10.1073/pnas.2200708119. View

Reinholz M, Ruzicka T, Steinhoff M, Schaller M, Gieler U, Schofer H . Pathogenese und Klinik der Rosazea als Schlüssel für eine symptomorientierte Therapie. J Dtsch Dermatol Ges. 2016; 14 Suppl 6:4-16. DOI: 10.1111/ddg.13139_g. View

Wu W, Geng H, Cho E, Eliassen A, Drucker A, Li T . Reproductive and hormonal factors and risk of incident rosacea among US White women. J Am Acad Dermatol. 2021; 87(1):138-140. DOI: 10.1016/j.jaad.2021.06.865. View

Wilkin J, Dahl M, Detmar M, Drake L, Liang M, Odom R . Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol. 2004; 50(6):907-12. DOI: 10.1016/j.jaad.2004.01.048. View

10.

Steinhoff M, Schauber J, Leyden J . New insights into rosacea pathophysiology: a review of recent findings. J Am Acad Dermatol. 2013; 69(6 Suppl 1):S15-26. DOI: 10.1016/j.jaad.2013.04.045. View

11.

Forton F . Rosacea, an infectious disease: why rosacea with papulopustules should be considered a demodicosis. A narrative review. J Eur Acad Dermatol Venereol. 2022; 36(7):987-1002. DOI: 10.1111/jdv.18049. View

12.

Forton F . The Pathogenic Role of Demodex Mites in Rosacea: A Potential Therapeutic Target Already in Erythematotelangiectatic Rosacea?. Dermatol Ther (Heidelb). 2020; 10(6):1229-1253. PMC: 7649190. DOI: 10.1007/s13555-020-00458-9. View

13.

Kim N, Lee S, Lee S, Kang J, Choi Y, Park J . Portable Cold Atmospheric Plasma Patch-Mediated Skin Anti-Inflammatory Therapy. Adv Sci (Weinh). 2022; 9(34):e2202800. PMC: 9731685. DOI: 10.1002/advs.202202800. View

14.

Casas C, Paul C, Lahfa M, Livideanu B, Lejeune O, Alvarez-Georges S . Quantification of Demodex folliculorum by PCR in rosacea and its relationship to skin innate immune activation. Exp Dermatol. 2012; 21(12):906-10. DOI: 10.1111/exd.12030. View

15.

Heinlin J, Morfill G, Landthaler M, Stolz W, Isbary G, Zimmermann J . Plasma medicine: possible applications in dermatology. J Dtsch Dermatol Ges. 2010; 8(12):968-76. DOI: 10.1111/j.1610-0387.2010.07495.x. View

16.

Kisch T, Schleusser S, Helmke A, Mauss K, Wenzel E, Hasemann B . The repetitive use of non-thermal dielectric barrier discharge plasma boosts cutaneous microcirculatory effects. Microvasc Res. 2016; 106:8-13. DOI: 10.1016/j.mvr.2016.02.008. View

17.

Bewley A, Fowler J, Schofer H, Kerrouche N, Rives V . Erythema of Rosacea Impairs Health-Related Quality of Life: Results of a Meta-analysis. Dermatol Ther (Heidelb). 2016; 6(2):237-47. PMC: 4906100. DOI: 10.1007/s13555-016-0106-9. View

18.

Borchardt T, Helmke A, Ernst J, Emmert S, Schilling A, Felmerer G . Topically Confined Enhancement of Cutaneous Microcirculation by Cold Plasma. Skin Pharmacol Physiol. 2022; 35(6):343-353. PMC: 9811424. DOI: 10.1159/000527700. View

19.

Lee Y, Lee M, Kim H, Won H, Kim C . Non-thermal atmospheric plasma ameliorates imiquimod-induced psoriasis-like skin inflammation in mice through inhibition of immune responses and up-regulation of PD-L1 expression. Sci Rep. 2017; 7(1):15564. PMC: 5686068. DOI: 10.1038/s41598-017-15725-7. View

20.

Busco G, Robert E, Chettouh-Hammas N, Pouvesle J, Grillon C . The emerging potential of cold atmospheric plasma in skin biology. Free Radic Biol Med. 2020; 161:290-304. DOI: 10.1016/j.freeradbiomed.2020.10.004. View